Deutsche Bank’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-23,515
| Closed | -$795K | – | 4825 |
|
|
2021
Q2 | $795K | Sell |
23,515
-502,856
| -96% | -$12.8M | ﹤0.01% | 2926 |
|
|
2021
Q1 | $12.3M | Sell |
526,371
-58,372
| -10% | -$1.77M | 0.01% | 1096 |
|
|
2020
Q4 | $16.8M | Buy |
584,743
+523,174
| +850% | +$13.2M | 0.01% | 843 |
|
|
2020
Q3 | $1.25M | Buy |
61,569
+46,055
| +297% | +$1.12M | ﹤0.01% | 2052 |
|
|
2020
Q2 | $466K | Buy |
15,514
+8,789
| +131% | +$317K | ﹤0.01% | 2679 |
|
|
2020
Q1 | $211K | Buy |
6,725
+1,143
| +20% | +$39.7K | ﹤0.01% | 2927 |
|
|
2019
Q4 | $261K | Buy |
5,582
+1,065
| +24% | +$30.7K | ﹤0.01% | 3062 |
|
|
2019
Q3 | $28K | Sell |
4,517
-42
| -0.9% | -$351 | ﹤0.01% | 4209 |
|
|
2019
Q2 | $55K | Sell |
4,559
-15,561
| -77% | -$173K | ﹤0.01% | 4475 |
|
|
2019
Q1 | $270K | Buy |
20,120
+14,781
| +277% | +$132K | ﹤0.01% | 3821 |
|
|
2018
Q4 | $21K | Sell |
5,339
-4,768
| -47% | -$28.7K | ﹤0.01% | 4730 |
|
|
2018
Q3 | $68K | Buy |
+10,107
| New | +$96.3K | ﹤0.01% | 4624 |
|
Deutsche Bank's CNST Position: Q3 2021 in Review
Deutsche Bank sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 23,515 shares — an estimated $795K sold.
Deutsche Bank first reported a position in CNST in Q3 2018 and held it in 12 quarters. The position peaked at $16.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.
- Deutsche Bank reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Deutsche Bank sold 23,515 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $795K.
- Deutsche Bank first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 12 quarters.
- Deutsche Bank's Constellation Pharmaceuticals, Inc. position peaked at $16.8M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.
Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.